inv-01: TransCyte — proven indication
TransCyte is proven and medically necessary for the following burn indications. All other uses are considered unproven and not medically necessary.
TransCyte (TransCyte™) is covered when ALL of the following are met:
- The wound is a surgically excised full‑thickness thermal burn or a deep partial‑thickness thermal burn AND
- The product is applied prior to autograft placement as a temporary biologic dressing to facilitate wound bed preparation and coverage.
Operational note: TransCyte is considered unproven and not medically necessary for indications other than those listed above.
inv-02: EpiFix/Grafix — diabetic foot ulcer (members <18)
EpiFix and Grafix products are proven and medically necessary for treating diabetic foot ulcers in members under 18 years of age when the following ALL criteria are met. Application frequency and duration limits apply.
Covered when ALL of the following are met:
- Member is under 18 years of age.
- Diagnosis of a diabetic foot ulcer (DFU) that does not extend to tendon, muscle, capsule, or bone.
- Adequate circulation to the affected extremity as shown by one or more of:
- Pedal pulses palpable or pulses confirmed with Doppler examination;
- Ankle‑brachial index (ABI) between 0.7 and 1.2.
- Glycated hemoglobin (HbA1c) < 12% within the last 90 days.
inv-03: Adjunctive use with standard of care
Adjunctive use of skin and soft tissue substitutes with standard of care (SOC) is recognized in the evidence base. Coverage as an adjunct to SOC requires documentation that SOC has been applied and that the adjunctive product is intended to supplement—not replace—standard therapies.
Covered as an adjunct to standard of care when ALL of the following are met:
- Standard of care appropriate for the wound type has been applied and documented (for DFUs: offloading, debridement as needed, infection control, and moisture‑balanced dressings; for VLUs: multilayer compression and local wound care; for other chronic wounds: documented appropriate SOC).
- The wound has failed to progress adequately with SOC alone (for example, <50% reduction in wound size after an appropriate SOC trial, commonly 4 weeks unless otherwise clinically justified).
- The adjunctive product is used in conjunction with ongoing SOC and not as a standalone substitute for required measures (e.g., continued offloading or compression as applicable).
inv-04: Adjunctive therapy — conditional coverage
Certain adjunctive therapy uses are conditionally covered where evidence suggests benefit but quality limitations or study heterogeneity impose constraints. Conditional coverage is subject to documented SOC failure, adherence to application limits, and monitoring of outcomes.
Conditional coverage applies when ALL of the following are met:
- The product is being used as an adjunct to documented SOC for an appropriate wound type.
- Product‑specific application frequency, maximum number of applications, and treatment duration limits from the evidence are followed.
- Treating clinician documents clinical response (for example, percent area reduction at standard checkpoints such as 4 and 12 weeks) and provides a plan for next steps if the wound is nonresponsive.
- Use is limited to indications and wound severities reflected in the supporting evidence (e.g., noninfected, adequately perfused chronic DFUs or VLUs that meet trial enrollment characteristics).
inv-05: Products with insufficient evidence
The products listed below have insufficient or inconclusive evidence to support coverage for the indications described. Statements are product‑specific and summarize the evidence gap or lack of studies.
Products with few or no studies are considered unproven and not medically necessary for all indications until adequate evidence is available. For example: Abiomend Membrane/Hydromembrane, Abiomend Xplus products, ACApatch, Acesso family products, Activate Matrix, AdvoGraft products, AeroGuard/NeoGuard, AlloGen, alloPLY, AlloSkin, AlloWrap, Altiply, and many others listed in the product catalog sections.
For products with limited published data, the policy conclusion is: insufficient evidence to determine clinical benefit — coverage not supported outside of research settings.
Operational note: Documentation of lack of prior adequate trials with evidence‑based products may be requested prior to approving investigational or exceptional coverage.
(See the comprehensive product list in the policy body for all named products judged investigational/insufficient.)
inv-06: COVERAGE CRITERIA — summary coverage stance across listed products
Summary coverage stance across listed products: where RCT or comparative evidence demonstrates benefit (primarily DFUs and some VLUs with specific amniotic or cellular products), coverage is supported under the stated criteria. Products lacking robust evidence remain unproven and not medically necessary.
- Covered (when criteria met): Selected products with RCT evidence for DFUs or VLUs (examples: certain dHACA products like AmnioBand when meeting trial‑like criteria; EpiFix and Grafix for DFUs under their stated limits; TransCyte for specified burn indications).
- Conditionally covered: adjunctive use of dermal matrices and amniotic products with SOC when evidence shows benefit but has quality limitations — requires documentation and adherence to application limits.
- Not covered / investigational: products without adequate clinical evidence, including many named amniotic, dermal, xenograft, and synthetic substitutes (see product lists).
inv-07: Products with insufficient/inconclusive evidence
The following products have insufficient or inconclusive evidence for effectiveness; summaries and policy conclusions follow the product‑level evidence statements in the policy body.
This group consolidates products judged investigational or not medically necessary due to lack of high‑quality studies, small sample sizes, or inconsistent outcomes across trials. Examples include many brand‑named products listed elsewhere in the policy (Grafix Core, Grafix Plus, Grafix PL line for off‑label uses, numerous amniotic products, xenografts, and novel matrices).
Policy conclusion: These products are considered investigational / not medically necessary for indications without supportive controlled clinical data. Coverage may be reconsidered if robust RCTs or high‑quality comparative studies demonstrating clinically meaningful benefit are published.
inv-08: dHACA / AmnioBand evidence summary
Amniotic products processed as dehydrated human amnion/chorion allograft (dHACA) and some aseptically processed amniotic products have the strongest and most consistent RCT evidence for diabetic foot ulcers and venous leg ulcers in selected populations. Coverage is product‑specific and requires meeting the stated clinical criteria.
Products with more substantial evidence (coverage‑relevant criteria):
- dHACA (example: AmnioBand / Guardian): covered for DFUs and VLUs when trial‑like enrollment criteria are met (adequate perfusion, noninfected wound, prior SOC trial, wound size/duration consistent with studied populations) and when applied per trial schedules (typically weekly up to 12 weeks).
- Other amniotic products with RCT support (certain EpiFix and Grafix studies for DFUs): covered under the EpiFix/Grafix DFU criteria and application limits.
Operational note: When requesting coverage for these products, documentation should include wound characteristics, prior SOC details and duration, perfusion measures, HbA1c when diabetic, and planned application frequency/duration consistent with evidence.
inv-09: Evidence-summary and trial eligibility
Clinical trial eligibility elements commonly used in the evidence base are informative for coverage determinations. When coverage is requested, documenting these elements supports alignment with trial populations and outcomes.
Typical trial eligibility and monitoring elements used in evidence that are relevant to coverage decisions:
- Age and comorbidity criteria (e.g., adult populations ≥18 in most trials; pediatric coverage exceptions are specified where evidence exists).
- Wound perfusion measures (ABI, TCOM, SPP) within acceptable ranges used in trials.
- Wound characteristics: size limits (commonly 0.5–25 cm2), duration (>1 month typical for chronic wounds), and depth not involving tendon/muscle/bone for many trials.
- Prior SOC trial documented (commonly 2–4 weeks of standardized care without adequate progression).
inv-10: Coverage conclusions by product (informational)
Product‑level coverage conclusions (informational): the policy maps available evidence to practical coverage rules. See the specific product sections for criteria, frequency limits, application windows, and investigational determinations.
Use the product‑specific sections in the policy body to determine whether a named product is covered, conditionally covered, or investigational.
For covered products, ensure documentation meets the listed criteria (perfusion, prior SOC, wound characteristics, application limits).
For investigational products, coverage is not supported unless enrolled in an approved clinical trial or per explicit payer exception processes.
inv-11: Biovance clinical evidence summary
Biovance registry data suggest safety and potential real‑world benefit, but registry findings require prospective RCT confirmation before broad coverage expansion.
- Registry reports suggest a substantial proportion of chronic wounds achieved closure in routine practice while using Biovance products; median time to closure and safety signals were acceptable in registry contexts.
- Biovance may be considered on a case‑by‑case basis when documentation mirrors populations in the registry, but broader coverage expansion awaits randomized controlled trial confirmation.
inv-12: Insufficient evidence / investigational — product list
The products named in the detailed product lists that follow are judged investigational or not medically necessary due to insufficient evidence. This list is updated as new evidence becomes available.
Products judged investigational / insufficient evidence include (non‑exhaustive list drawn from policy body): many amniotic membrane products, xenograft matrices, certain dermal matrices, and newer biologic dressings (see the comprehensive listings in the policy body).
Policy conclusion: These products are not covered for clinical indications lacking robust comparative evidence. Requests for coverage require submission of peer‑reviewed comparative data demonstrating clinically meaningful benefit.
inv-13: CorMatrix (porcine SIS-ECM) – insufficient evidence for some cardiac applications
CorMatrix (porcine small intestinal submucosa extracelular matrix — SIS‑ECM) has been used in a range of cardiac applications. Current evidence is limited and reports raise concerns about patch failure in some valve and leaflet augmentation uses.
Evidence summary and policy conclusion:
- CorMatrix has limited and conflicting observational evidence in cardiac surgery applications (e.g., patching in congenital repairs, mitral leaflet augmentation).
- Reported complications in some series include high rates of patch failure, recurrent valvular dysfunction, and need for reoperation in mitral valve leaflet augmentation when compared to autologous pericardium in small series.
- Given study limitations (retrospective designs, small samples, heterogeneous populations), evidence is insufficient to support broad coverage for certain cardiac reconstructive indications.
inv-15: Evidence statements by product
Product‑specific evidence statements summarize available studies and inform the policy's coverage determinations. Where evidence is lacking, products remain investigational.
Clinicians seeking coverage for specific products should reference the product‑level evidence summaries elsewhere in the policy that describe RCTs, registries, meta‑analyses, and limitations that underlie coverage positions.
The policy will be updated as higher‑quality evidence becomes available for individual products.
inv-16: Coverage criteria and expected outcomes
Coverage considerations and typical study inclusion criteria guide the practical application of coverage rules and expected outcomes used to evaluate requests.
Coverage criteria emphasize the following elements: adequate perfusion, absence of active infection, documented trial of SOC, wound characteristics consistent with trial populations, appropriate glycemic control when diabetic, and adherence to product application schedules.
Expected outcomes used in evidence assessments include percent area reduction at 4 weeks, proportion healed at 12 weeks, time to complete healing, and rates of adverse events including infection and amputation.
Documentation aligning with these considerations increases the likelihood that an application matches evidence‑based use cases.
inv-17: Evidence-based coverage conclusions and product-level determinations
Evidence‑based coverage conclusions and product determinations summarized for clinician reference.
Where randomized controlled or high‑quality comparative evidence exists demonstrating benefit versus standard of care, the policy supports coverage under defined clinical criteria.
Where evidence is low‑quality, small, or conflicting, the policy limits coverage to conditional or investigational pathways, requiring more stringent documentation or participation in research.
inv-18: Implied coverage groups based on evidence sufficiency
Implied coverage groups and their supporting conditions: when evidence is sufficient for a product class (e.g., selected amniotic allografts) coverage is aligned to product‑specific criteria; otherwise, products remain investigational.
Implied coverage groups include:
- Amniotic membranes/dHACA with supportive RCT data for DFUs/VLUs — coverage when trial‑like criteria are met.
- Cellular dermal substitutes with limited comparative evidence — conditional or investigational depending on product and indication.
- Xenograft or novel ECM products with mixed or limited data — investigational until robust comparative evidence exists.
inv-19: Coverage conclusions by product (additional)
Additional product‑level conclusions across other sections of the policy are summarized here for operational clarity.
Clinicians should consult individual product subsections for application limits, clinical trial summaries, and the policy's investigational notations when preparing coverage requests.
Where product sections indicate inadequate evidence, requests for coverage are generally denied unless compelling comparative data or trial enrollment is documented.